Navigation Links
Annals of Internal Medicine tip sheet for Feb. 5, 2008, issue
Date:2/4/2008

1. No Clear Winner in Comparative Review of Effectiveness and Harms of Treatments for Localized Prostate Cancer

About 197,000 men will be diagnosed with clinically localized prostate cancer (cancer confined to the prostate gland) in 2008. Common treatments include watchful waiting, surgery to remove the prostate gland, radiotherapy, and androgen deprivation.

A review of these treatments concluded, Accurately assessing comparative effectiveness and harms of localized prostate cancer treatments is difficult due to limitations in the evidence. All treatments result in adverse events, primarily to urinary, bowel and sexual function, that occur soon after therapy, though the frequency, duration and severity may vary between treatments.

Note: This systematic review is being released early online at the Web site of Annals of Internal Medicine www.annals.org. It will appear in the March 18, 2008, print edition of the journal.


2. Gene Expression Tests for Breast Cancer Are Promising But Limited

A review of three commercial gene expression-based prognostic breast cancer tests finds they have potential for improving prognostic and therapeutic prediction, but more data are needed about the amount of improvement, which women will benefit, and how to use the test in decision making about current breast cancer treatment.

Note: This systematic review is being released early online at the Web site of Annals of Internal Medicine www.annals.org. It will appear in the March 18, 2008, print edition of the journal.


3. New Study Refines Thinking on Best Time to Begin HIV Treatment

Debate about the optimal time to begin HIV treatment continues, partly because current mathematical models that weigh harms and benefits over long horizons do not consider drug toxicity and side effects and accrual of HIV drug resistance mutations, which are the primary risks of initiating therapy early.

A new computer simulation incorporates toxicity and side effects of combination antiretroviral therapy (Article, p. 178). It suggests that initiation of combination antiretroviral therapy when the CD4 count falls below 500 cells/mm may increase the life expectancy and quality-adjusted life expectancy of younger patients, particularly if they have higher viral loads.

The simulation also strengthens the case for treating patients with CD4 counts between 200 and 350 cells/mm compared with current guidelines.


4. Expert Group: Do Not Screen Pregnant Women for Bacterial Vaginosis

Bacterial vaginosis is the most common lower genital tract syndrome among women of reproductive age and has been associated with premature births or low birthweight. Because bacterial vaginosis is easy to screen for and treat, some favor screening all pregnant women for it.

But the U.S. Preventive Services Task Force (USPSTF) recommends against screening low-risk women for bacterial vaginosis because there is good evidence that treating the syndrome does not benefit pregnant women at low risk for premature delivery (Clinical Guidelines, p. 214; Update Review, p. 220).

The task force finds insufficient evidence to recommend either for or against screening for the syndrome in pregnant women at high risk for premature delivery.


'/>"/>

Contact: Susan Anderson
sanderson@acponline.org
215-351-2653
American College of Physicians
Source:Eurekalert

Related medicine news :

1. Annals of Internal Medicine tip sheet for Aug. 21, 2007, issue
2. September/October 2007 Annals of Family Medicine tip sheet
3. Annals of Internal Medicine tip sheet for Oct. 2
4. Annals of Internal Medicine Tip Sheet for Nov. 20, 2007, Issue
5. Annals of Internal Medicine tip sheet for Jan. 1, 2008, issue
6. Pharmaceutical Manufacturing Quality: Optimizing Your Internal Process for FDA Compliance
7. Internal medicine physicians recommend key elements to guide state initiatives
8. Internal radiotherapy better than external for quality of life in endometrial cancer patients
9. Sunrise Provides Status Report on Special Independent Committee Investigation; Provides Updates on Managements Internal Control Review Efforts and on Legal Proceedings
10. Michigan Catholic Conference Launches Massive Internal Stem Cell Education Program
11. Barta joins Conseco as Senior Vice President, Financial Planning & Analysis; Barra named Senior Vice President, Internal Audit; Clarke to head Investor Relations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... 2016 , ... TherapySites, the leading website and ... Tennessee Counseling Association. This new relationship allows TherapySites to continue to extend ... exclusive benefits and promotional offers. , "TCA is extremely excited about this new ...
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A Forever Recovery, ... Festival and World’s Longest Breakfast Table in Battle Creek, MI, where the rehabilitation facility ... home to some of the world’s leading providers of cereal and other breakfast foods. ...
(Date:6/25/2016)... , ... June 25, 2016 , ... ... policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at ... on several important health care topics including advance care planning, healthcare costs and ...
(Date:6/25/2016)... , ... June 25, 2016 , ... As a lifelong ... Cum Laude and his M.D from the David Geffen School of Medicine at UCLA. ... to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Those who have ... these feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, as ... Michigan, has released tools for healthy coping following a traumatic event. , Trauma sufferers ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Research and Markets has announced the addition of ... report to their offering. ... kidney failure, it replaces the function of kidneys by removing ... thus the treatment helps to keep the patient body,s electrolytes ... Increasing number of ESRD patients & substantial healthcare expenditure ...
(Date:6/23/2016)... 23, 2016 Roche (SIX: RO, ROG; OTCQX: ... its Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated ... shock. With this clearance, Roche is the first IVD ... solution for sepsis risk assessment and management. ... and PCT levels in blood can aid clinicians in ...
(Date:6/23/2016)... Bracket , a leading clinical trial technology ... outcomes platform, Bracket eCOA (SM) 6.0, at the 52 ... 30, 2016 in Philadelphia , Pennsylvania.  A ... product of its kind to fully integrate with RTSM, will ... 6.0 is a flexible platform for electronic clinical outcomes assessments ...
Breaking Medicine Technology: